MIDTERM & FINAL EXAM STUDY GUIDE REVIEW
CHAMBERLAIN UNIVERSITY · COLLEGE OF NURSING
NR 546
Advanced Pharmacology
Psychopharmacology
for the Psychiatric-Mental Health
Nurse Practitioner
Comprehensive 150-Question Review — Latest Update
This study guide delivers 150 board-style multiple-choice questions with detailed rationales across ten
psychopharmacology domains: principles of pharmacology, neurobiology, antidepressants, antipsychotics, mood
stabilizers, anxiolytics, psychostimulants, substance use disorder pharmacotherapy, special populations, and
integrated case studies. Items are calibrated to NR 546 course outcomes, AACN Essentials of Master's
Education, and PMHNP psychopharmacology competencies, with a cognitive distribution of 20% recall, 50%
application, and 30% analysis.
COURSE PROGRAM EDITION
NR 546 PMHNP-MSNL/track
A l ig n e d w i t h C h a mb e r l a i n N R 5 4 6 Syl l a b u s · A A C N E s s e n t ia l s · P M H N P P sych o p h a r m a c o l o g y C o m p e t e n c ie s
,NR 546 Advanced Pharmacology Psychopharmacology Midterm & Final Exam Study Guide Review |
NR 546 Advanced Pharmacology Psychopharmacology
Midterm & Final Exam Study Guide Review ()
This comprehensive 150-question study guide is designed for graduate nursing students preparing for the NR 546
Advanced Pharmacology Psychopharmacology Midterm and Final examinations. The content is aligned with the
Chamberlain University NR 546 course syllabus, AACN Essentials of Master's Education in Nursing, and the
Psychiatric-Mental Health Nurse Practitioner (PMHNP) Psychopharmacology Competencies (2026/2027 Edition).
Each question includes four answer choices with the correct response marked and a detailed rationale linking the
answer to psychopharmacology principles, mechanisms of action, clinical monitoring parameters, and
evidence-based practice.
The cognitive level distribution is 20% recall, 50% application, and 30% analysis, reflecting the board-style
assessment approach used in PMHNP certification examinations. Approximately 75% of questions are
scenario-based, requiring clinical reasoning, medication selection, side effect management, and patient education
decisions. The remaining 25% assess foundational pharmacologic knowledge including mechanisms, indications,
and pharmacokinetics.
Examination Structure
Section 1: Principles of Psychopharmacology (20 questions) | Section 2: Neurobiology & Neurotransmitters (15) |
Section 3: Antidepressants (20) | Section 4: Antipsychotics (20) | Section 5: Mood Stabilizers (15) | Section 6:
Anxiolytics & Sedative-Hypnotics (15) | Section 7: Psychostimulants & ADHD Medications (12) | Section 8:
Substance Use Disorder Pharmacotherapy (13) | Section 9: Special Populations & Advanced Practice
Considerations (10) | Section 10: Comprehensive Case Studies & Medication Management (10). Total: 150
questions.
How to Use This Guide
Attempt each question before reading the rationale. Review the rationale carefully even for correctly answered
items to reinforce the underlying psychopharmacology principle. Use the section structure to organize study
sessions and target weaker domains. The case studies in Section 10 integrate multiple concepts and best simulate the
clinical reasoning required on PMHNP board examinations.
Chamberlain University | PMHNP Track Page 1
,NR 546 Advanced Pharmacology Psychopharmacology Midterm & Final Exam Study Guide Review |
Section 1: Principles of Psychopharmacology
Pharmacokinetics, pharmacodynamics, CYP450 enzymes, pharmacogenomics, therapeutic drug monitoring, drug
interactions, controlled substances, and prescriptive authority.
Q1: A 42-year-old patient is started on oral fluoxetine 20 mg daily for major depressive disorder. The
PMHNP understands that the first-pass effect primarily reduces the bioavailability of orally administered
medications through which mechanism?
A. Binding of the drug to plasma proteins reducing free drug available to receptors
B. Metabolism of the drug by CYP3A4 enzymes in the intestinal lumen before systemic absorption
C. Metabolism of the drug by hepatic enzymes before the medication reaches systemic circulation
*[CORRECT]*
D. Active transport of the drug back into the intestinal lumen by P-glycoprotein
Correct Answer: C
Rationale: The first-pass (presystemic) effect refers to metabolism of an orally administered drug by hepatic enzymes in the
liver before it reaches systemic circulation, reducing bioavailability. While intestinal CYP3A4 (option A) and P-glycoprotein
efflux (option C) also contribute to presystemic loss, the classic first-pass effect specifically describes hepatic metabolism.
Protein binding (option D) affects distribution, not first-pass metabolism.
Q2: A patient taking fluoxetine 20 mg daily for depression is newly prescribed metoprolol for hypertension.
The PMHNP anticipates which interaction, and what monitoring is required?
A. Fluoxetine displaces metoprolol from protein binding; monitor for tachycardia
B. Fluoxetine induces CYP3A4, decreasing metoprolol levels; monitor for inadequate BP control
C. Fluoxetine inhibits P-glycoprotein, increasing metoprolol CNS penetration; monitor for sedation
D. Fluoxetine inhibits CYP2D6, increasing metoprolol levels; monitor for bradycardia and hypotension
*[CORRECT]*
Correct Answer: D
Rationale: Fluoxetine and paroxetine are potent CYP2D6 inhibitors. Metoprolol is metabolized by CYP2D6, so
coadministration can increase metoprolol exposure, leading to exaggerated beta-blockade (bradycardia, hypotension). NR 546
emphasizes recognition of CYP2D6 inhibition patterns; options B, C, and D misattribute the enzymatic pathway or mechanism
of interaction.
Q3: Pharmacogenomic testing reveals a patient is a CYP2D6 poor metabolizer. Which psychotropic
medication would be most affected, requiring dose reduction or alternative selection?
A. Atomoxetine, because CYP2D6 is the primary metabolic pathway and poor metabolizers have markedly
increased exposure *[CORRECT]*
B. Lithium, because CYP2D6 polymorphisms reduce renal excretion
C. Venlafaxine, because CYP2D6 converts it to the active metabolite O-desmethylvenlafaxine
D. Quetiapine, because CYP2D6 inhibition significantly reduces its clearance
Correct Answer: A
Rationale: Atomoxetine is metabolized almost exclusively by CYP2D6, and poor metabolizers exhibit up to 10-fold higher
AUC, requiring dose reduction to avoid adverse effects. Venlafaxine is also CYP2D6-metabolized but conversion to
desvenlafaxine is not the only pathway. Quetiapine is primarily CYP3A4-metabolized, and lithium is renally excreted without
CYP metabolism. CPIC guidelines inform atomoxetine dosing based on CYP2D6 phenotype.
Chamberlain University | PMHNP Track Page 2
, NR 546 Advanced Pharmacology Psychopharmacology Midterm & Final Exam Study Guide Review |
Q4: The blood-brain barrier restricts CNS penetration of many psychotropic medications. Which
transporter is most responsible for actively effluxing drugs back into the systemic circulation at the BBB?
A. Organic anion transporting polypeptide (OATP) at the abluminal membrane
B. P-glycoprotein (ABCB1) expressed on the luminal membrane of brain capillary endothelial cells
*[CORRECT]*
C. CYP3A4 expressed in brain capillary endothelium
D. Breast cancer resistance protein (BCRP) at the choroid plexus only
Correct Answer: B
Rationale: P-glycoprotein (P-gp, encoded by ABCB1) on the luminal membrane of brain capillary endothelial cells actively
pumps many drugs (e.g., risperidone, loperamide) back into the blood, limiting CNS penetration. While BCRP (option D)
contributes, P-gp is the dominant efflux transporter at the BBB. CYP3A4 (option A) metabolizes rather than effluxes, and
OATP (option C) typically mediates uptake, not efflux.
Q5: Therapeutic drug monitoring is essential for several psychotropic agents. Which of the following
medications requires routine serum level monitoring to balance efficacy against a narrow therapeutic
window?
A. Quetiapine, because serum levels correlate tightly with clinical response
B. Sertraline, because its therapeutic window is 50-150 ng/mL
C. Bupropion, because serum levels predict seizure threshold
D. Lithium, because its therapeutic window is narrow (0.6-1.2 mEq/L) and toxicity can be life-threatening
*[CORRECT]*
Correct Answer: D
Rationale: Lithium has a notoriously narrow therapeutic index (0.6-1.2 mEq/L for maintenance, 0.8-1.0 mEq/L for acute
mania); levels above 1.5 mEq/L risk tremor, ataxia, and seizures, while levels above 2.5 mEq/L can be fatal. SSRIs (option A),
atypical antipsychotics like quetiapine (option C), and bupropion (option D) do not require routine serum monitoring. AACN
Essentials emphasize safe prescribing through TDM for high-risk agents.
Q6: A 68-year-old patient is prescribed multiple psychotropic medications. Which age-related
pharmacokinetic change most increases the risk of adverse drug reactions in older adults?
A. Decreased hepatic blood flow and CYP enzyme activity prolonging drug half-life *[CORRECT]*
B. Increased total body water raising volume of distribution for lipophilic drugs
C. Increased gastric acidity leading to faster absorption of basic drugs
D. Increased glomerular filtration rate accelerating renal excretion
Correct Answer: A
Rationale: Aging reduces hepatic blood flow and CYP enzyme activity (especially CYP3A4 and CYP2C19), prolonging the
half-life of hepatically cleared psychotropics (e.g., benzodiazepines, trazodone). Lipophilic drug volume of distribution actually
increases with age due to increased body fat (not water), and GFR declines. These changes underpin Beers Criteria warnings
and the geriatric prescribing principle 'start low, go slow.'
Chamberlain University | PMHNP Track Page 3
CHAMBERLAIN UNIVERSITY · COLLEGE OF NURSING
NR 546
Advanced Pharmacology
Psychopharmacology
for the Psychiatric-Mental Health
Nurse Practitioner
Comprehensive 150-Question Review — Latest Update
This study guide delivers 150 board-style multiple-choice questions with detailed rationales across ten
psychopharmacology domains: principles of pharmacology, neurobiology, antidepressants, antipsychotics, mood
stabilizers, anxiolytics, psychostimulants, substance use disorder pharmacotherapy, special populations, and
integrated case studies. Items are calibrated to NR 546 course outcomes, AACN Essentials of Master's
Education, and PMHNP psychopharmacology competencies, with a cognitive distribution of 20% recall, 50%
application, and 30% analysis.
COURSE PROGRAM EDITION
NR 546 PMHNP-MSNL/track
A l ig n e d w i t h C h a mb e r l a i n N R 5 4 6 Syl l a b u s · A A C N E s s e n t ia l s · P M H N P P sych o p h a r m a c o l o g y C o m p e t e n c ie s
,NR 546 Advanced Pharmacology Psychopharmacology Midterm & Final Exam Study Guide Review |
NR 546 Advanced Pharmacology Psychopharmacology
Midterm & Final Exam Study Guide Review ()
This comprehensive 150-question study guide is designed for graduate nursing students preparing for the NR 546
Advanced Pharmacology Psychopharmacology Midterm and Final examinations. The content is aligned with the
Chamberlain University NR 546 course syllabus, AACN Essentials of Master's Education in Nursing, and the
Psychiatric-Mental Health Nurse Practitioner (PMHNP) Psychopharmacology Competencies (2026/2027 Edition).
Each question includes four answer choices with the correct response marked and a detailed rationale linking the
answer to psychopharmacology principles, mechanisms of action, clinical monitoring parameters, and
evidence-based practice.
The cognitive level distribution is 20% recall, 50% application, and 30% analysis, reflecting the board-style
assessment approach used in PMHNP certification examinations. Approximately 75% of questions are
scenario-based, requiring clinical reasoning, medication selection, side effect management, and patient education
decisions. The remaining 25% assess foundational pharmacologic knowledge including mechanisms, indications,
and pharmacokinetics.
Examination Structure
Section 1: Principles of Psychopharmacology (20 questions) | Section 2: Neurobiology & Neurotransmitters (15) |
Section 3: Antidepressants (20) | Section 4: Antipsychotics (20) | Section 5: Mood Stabilizers (15) | Section 6:
Anxiolytics & Sedative-Hypnotics (15) | Section 7: Psychostimulants & ADHD Medications (12) | Section 8:
Substance Use Disorder Pharmacotherapy (13) | Section 9: Special Populations & Advanced Practice
Considerations (10) | Section 10: Comprehensive Case Studies & Medication Management (10). Total: 150
questions.
How to Use This Guide
Attempt each question before reading the rationale. Review the rationale carefully even for correctly answered
items to reinforce the underlying psychopharmacology principle. Use the section structure to organize study
sessions and target weaker domains. The case studies in Section 10 integrate multiple concepts and best simulate the
clinical reasoning required on PMHNP board examinations.
Chamberlain University | PMHNP Track Page 1
,NR 546 Advanced Pharmacology Psychopharmacology Midterm & Final Exam Study Guide Review |
Section 1: Principles of Psychopharmacology
Pharmacokinetics, pharmacodynamics, CYP450 enzymes, pharmacogenomics, therapeutic drug monitoring, drug
interactions, controlled substances, and prescriptive authority.
Q1: A 42-year-old patient is started on oral fluoxetine 20 mg daily for major depressive disorder. The
PMHNP understands that the first-pass effect primarily reduces the bioavailability of orally administered
medications through which mechanism?
A. Binding of the drug to plasma proteins reducing free drug available to receptors
B. Metabolism of the drug by CYP3A4 enzymes in the intestinal lumen before systemic absorption
C. Metabolism of the drug by hepatic enzymes before the medication reaches systemic circulation
*[CORRECT]*
D. Active transport of the drug back into the intestinal lumen by P-glycoprotein
Correct Answer: C
Rationale: The first-pass (presystemic) effect refers to metabolism of an orally administered drug by hepatic enzymes in the
liver before it reaches systemic circulation, reducing bioavailability. While intestinal CYP3A4 (option A) and P-glycoprotein
efflux (option C) also contribute to presystemic loss, the classic first-pass effect specifically describes hepatic metabolism.
Protein binding (option D) affects distribution, not first-pass metabolism.
Q2: A patient taking fluoxetine 20 mg daily for depression is newly prescribed metoprolol for hypertension.
The PMHNP anticipates which interaction, and what monitoring is required?
A. Fluoxetine displaces metoprolol from protein binding; monitor for tachycardia
B. Fluoxetine induces CYP3A4, decreasing metoprolol levels; monitor for inadequate BP control
C. Fluoxetine inhibits P-glycoprotein, increasing metoprolol CNS penetration; monitor for sedation
D. Fluoxetine inhibits CYP2D6, increasing metoprolol levels; monitor for bradycardia and hypotension
*[CORRECT]*
Correct Answer: D
Rationale: Fluoxetine and paroxetine are potent CYP2D6 inhibitors. Metoprolol is metabolized by CYP2D6, so
coadministration can increase metoprolol exposure, leading to exaggerated beta-blockade (bradycardia, hypotension). NR 546
emphasizes recognition of CYP2D6 inhibition patterns; options B, C, and D misattribute the enzymatic pathway or mechanism
of interaction.
Q3: Pharmacogenomic testing reveals a patient is a CYP2D6 poor metabolizer. Which psychotropic
medication would be most affected, requiring dose reduction or alternative selection?
A. Atomoxetine, because CYP2D6 is the primary metabolic pathway and poor metabolizers have markedly
increased exposure *[CORRECT]*
B. Lithium, because CYP2D6 polymorphisms reduce renal excretion
C. Venlafaxine, because CYP2D6 converts it to the active metabolite O-desmethylvenlafaxine
D. Quetiapine, because CYP2D6 inhibition significantly reduces its clearance
Correct Answer: A
Rationale: Atomoxetine is metabolized almost exclusively by CYP2D6, and poor metabolizers exhibit up to 10-fold higher
AUC, requiring dose reduction to avoid adverse effects. Venlafaxine is also CYP2D6-metabolized but conversion to
desvenlafaxine is not the only pathway. Quetiapine is primarily CYP3A4-metabolized, and lithium is renally excreted without
CYP metabolism. CPIC guidelines inform atomoxetine dosing based on CYP2D6 phenotype.
Chamberlain University | PMHNP Track Page 2
, NR 546 Advanced Pharmacology Psychopharmacology Midterm & Final Exam Study Guide Review |
Q4: The blood-brain barrier restricts CNS penetration of many psychotropic medications. Which
transporter is most responsible for actively effluxing drugs back into the systemic circulation at the BBB?
A. Organic anion transporting polypeptide (OATP) at the abluminal membrane
B. P-glycoprotein (ABCB1) expressed on the luminal membrane of brain capillary endothelial cells
*[CORRECT]*
C. CYP3A4 expressed in brain capillary endothelium
D. Breast cancer resistance protein (BCRP) at the choroid plexus only
Correct Answer: B
Rationale: P-glycoprotein (P-gp, encoded by ABCB1) on the luminal membrane of brain capillary endothelial cells actively
pumps many drugs (e.g., risperidone, loperamide) back into the blood, limiting CNS penetration. While BCRP (option D)
contributes, P-gp is the dominant efflux transporter at the BBB. CYP3A4 (option A) metabolizes rather than effluxes, and
OATP (option C) typically mediates uptake, not efflux.
Q5: Therapeutic drug monitoring is essential for several psychotropic agents. Which of the following
medications requires routine serum level monitoring to balance efficacy against a narrow therapeutic
window?
A. Quetiapine, because serum levels correlate tightly with clinical response
B. Sertraline, because its therapeutic window is 50-150 ng/mL
C. Bupropion, because serum levels predict seizure threshold
D. Lithium, because its therapeutic window is narrow (0.6-1.2 mEq/L) and toxicity can be life-threatening
*[CORRECT]*
Correct Answer: D
Rationale: Lithium has a notoriously narrow therapeutic index (0.6-1.2 mEq/L for maintenance, 0.8-1.0 mEq/L for acute
mania); levels above 1.5 mEq/L risk tremor, ataxia, and seizures, while levels above 2.5 mEq/L can be fatal. SSRIs (option A),
atypical antipsychotics like quetiapine (option C), and bupropion (option D) do not require routine serum monitoring. AACN
Essentials emphasize safe prescribing through TDM for high-risk agents.
Q6: A 68-year-old patient is prescribed multiple psychotropic medications. Which age-related
pharmacokinetic change most increases the risk of adverse drug reactions in older adults?
A. Decreased hepatic blood flow and CYP enzyme activity prolonging drug half-life *[CORRECT]*
B. Increased total body water raising volume of distribution for lipophilic drugs
C. Increased gastric acidity leading to faster absorption of basic drugs
D. Increased glomerular filtration rate accelerating renal excretion
Correct Answer: A
Rationale: Aging reduces hepatic blood flow and CYP enzyme activity (especially CYP3A4 and CYP2C19), prolonging the
half-life of hepatically cleared psychotropics (e.g., benzodiazepines, trazodone). Lipophilic drug volume of distribution actually
increases with age due to increased body fat (not water), and GFR declines. These changes underpin Beers Criteria warnings
and the geriatric prescribing principle 'start low, go slow.'
Chamberlain University | PMHNP Track Page 3
